Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><strong><em>Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 </em></strong></p><p align="justify">NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital (MGH), and Director of the Division of Clinical...